BioVie Inc Stock News

CARSON CITY, Nev., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the purchase and sale of 2,962,500 shares of...

CARSON CITY, Nev., Nov. 02, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the Company has been invited to present a late-breaking oral presentation at the 4th Long COVID International Conference 2026 to be held in Nice, France from Nov...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its experimental Parkinson's drug bezisterim improved both motor and non-motor symptoms in a subgroup of early-stage patients with higher systemic inflammation, according to Phase 2 SUNRISE-PD results presented at the American Neurological Association's annual meeting in San Diego.  The randomized, double-blind, placebo-controlled trial enrolled 57 pa...

Parkinson's patients elevated baseline inflammation demonstrated statistically significant improvements in both motor and non-motor symptoms with Bezisterim compared to placebo.  CARSON CITY, Nev.

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) said its Phase 2 ADDRESS-LC trial found that bezisterim delivered the greatest benefits in Long COVID patients with more severe baseline fatigue, post-exertional malaise (PEM) or cognitive impairment, with statistically significant improvements across multiple measures.  The results were presented at the American Neurological Association's annual meeting i...

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) will present results from two Phase 2 trials of its experimental drug bezisterim, in Long COVID and Parkinson's disease, at the American Neurological Association's annual meeting in San Diego.  The company said both abstracts were accepted as poster presentations at ANA2026, which runs from October 17 to 20.

Statistically significant benefits observed in bezisterim-treated Long COVID patients  in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise

BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) told investors that it is preparing to advance its Phase 3 development program for bezisterim in Parkinson's disease and has requested an End-of-Phase 2 meeting with the US Food and Drug Administration. The company is working with Parkinson's disease clinical development experts to finalize the design of a Phase 3 trial.